Dobutamine Injection
» Dobutamine Injection is a sterile solution of Dobutamine Hydrochloride in Water for Injection. It contains an amount of Dobutamine Hydrochloride equivalent to not less than 90.0 percent and not more than 110.0 percent of the labeled amount of dobutamine (C18H23NO3). It may contain one or more suitable antioxidants, chelating agents, or preservatives.
Packaging and storage— Preserve in single-dose or multiple-dose containers, preferably of Type I glass.
Labeling— Label it to indicate that it is to be diluted to appropriate strength with a suitable parenteral vehicle prior to administration.
USP Reference standards 11
USP Dobutamine Hydrochloride RS Click to View Structure
USP Endotoxin RS
Identification— A 10-µL volume of it responds to the Identification test under Dobutamine for Injection.
Bacterial endotoxins 85 It contains not more than 2.08 USP Endotoxin Units per mg of dobutamine.
pH 791: between 2.5 and 5.5.
Particulate matter 788: meets the requirements for small-volume Injections.
Other requirements— It meets the requirements under Injections 1.
Ion-pair solution— Dissolve 3.38 g of sodium 1-octanesulfonate in 1000 mL of water, pipet 3 mL of triethylamine into the solution, and mix. Adjust the solution with phosphoric acid to a pH of 2.5.
Mobile phase— Prepare a filtered and degassed mixture of the Ion-pair solution, acetonitrile, and methanol (58:28:14). Make adjustments if necessary (see System Suitability under Chromatography 621). [note—The ratio of acetonitrile to methanol is critical to the elution order of the System suitability solution components. ]
System suitability solution— Dissolve suitable quantities of 4-(4-hydroxyphenyl)-2-butanone and USP Dobutamine Hydrochloride RS in Mobile phase to obtain a solution containing about 0.3 and 0.56 mg per mL, respectively.
Standard preparation— Dissolve an accurately weighed quantity of USP Dobutamine Hydrochloride RS in Mobile phase and dilute quantitatively, and stepwise if necessary, with Mobile phase to obtain a solution having a known concentration of about 0.56 mg per mL (equivalent to about 0.5 mg of dobutamine per mL).
Assay preparation— Transfer an accurately measured volume of Injection, equivalent to about 25 mg of dobutamine, to a 50-mL volumetric flask. Dilute with Mobile phase to volume, and mix.
Chromatographic system (see Chromatography 621)—The liquid chromatograph is equipped with a 280-nm detector and a 4.6-mm × 25-cm column that contains 5-µm, base-deactivated packing L1. The flow rate is about 1 mL per minute. Chromatograph the System suitability solution, and record the peak responses as directed under Procedure: the relative retention times are about 0.9 for 4-(4-hydroxyphenyl)-2-butanone and 1.0 for dobutamine, the resolution, R, between 4-(4-hydroxyphenyl)-2-butanone and dobutamine is not less than 1.5; the tailing factor for dobutamine is not more than 1.5; and the relative standard deviation for replicate injections is not more than 2.0%.
Procedure— Separately inject equal volumes (about 20 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of C18H23NO3 in the portion of Injection taken by the formula:
(301.39 / 337.84)(50C)(rU / rS)
in which 301.39 is the molecular weight of dobutamine; 337.84 is the molecular weight of dobutamine hydrochloride; C is the concentration, in mg per mL, of USP Dobutamine Hydrochloride RS in the Standard preparation; and rU and rS are the peak responses obtained from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information— Please check for your question in the FAQs before contacting USP.
Topic/Question Contact Expert Committee
Monograph Sujatha Ramakrishna, Ph.D.
Senior Scientific Liaison
(SM22010) Monographs - Small Molecules 2
Reference Standards RS Technical Services
85 Radhakrishna S Tirumalai, Ph.D.
Principal Scientific Liaison
(GCM2010) General Chapters - Microbiology
USP35–NF30 Page 2951